Company intelligence / Profile preview
Curome Biosciences
Cheongju-si, South Koreacurome.co.kr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
HK-660S has received US Phase 2 IND approval and Orphan Drug Designation (ODD) for PSC from both US FDA (March 2022) and MFDS (June 2022). PSC Clinical 2a has been completed.
- Therapeutic areas
- GastroenterologyRare DiseasesNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Standigm Co., Ltd. (MOU signed to develop treatments for rare diseases using an AI-based platform)
Beyond the preview
Go deeper on Curome Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curome Biosciences.